Latest news with #VRNA
Yahoo
3 days ago
- Business
- Yahoo
Jim Cramer Notes Verona Pharma plc (VRNA) 'Loses a Lot of Money'
We recently published a list of . In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other stocks that Jim Cramer discusses. Answering a caller's query about Verona Pharma plc (NASDAQ:VRNA), Cramer stated: 'That stock is a rocket ship. Again, very very speculative, because it loses a lot of money. Does have a couple things in the pipe that people like, but also has a huge amount of insider selling, frankly.' A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma (NASDAQ:VRNA) is a biopharmaceutical company developing treatments for respiratory diseases with limited treatment options. The company's lead therapy, Ohtuvayre, is designed to provide bronchodilation and anti-inflammatory benefits for conditions like COPD, cystic fibrosis, and asthma. Buckley Capital Advisors stated the following regarding Verona Pharma plc (NASDAQ:VRNA) in its Q1 2025 investor letter: 'Verona Pharma plc (NASDAQ:VRNA) has developed a product called ensifentrine (Ohtuvayre), a bronchodilator and anti-inflammatory agent for maintenance treatment of COPD. COPD, more commonly known as smoker's lung, is caused by pollution or smoking. Diagnosis of COPD lowers life expectancy by approximately 6 years. Symptoms of COPD are shortness of breath, cough, wheezing, and sputum. COPD affects approximately 400 million people worldwide, with 8.6m people treated in the United States. Overall, VRNA ranks 7th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of VRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VRNA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
02-05-2025
- Business
- Yahoo
Why Verona Pharma plc (VRNA) Soared on Tuesday
We recently published an article titled . In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against the other stocks that soared on Tuesday. The stock market finished Tuesday's trading on a positive note with all major indices ending in the green, buoyed by the influx of corporate earnings results. The Dow Jones grew by 0.75 percent, the S&P 500 rose by 0.58 percent, and the Nasdaq was up by 0.55 percent. Ten companies mirrored the broader market optimism, leading the charge with strong gains, predominantly driven by impressive earnings results. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A patient in a clinic, taking a medication dose from a nebulizer to treat a respiratory disease. Verona Pharma plc (NASDAQ:VRNA) extended its rally for an eighth straight day on Tuesday, adding 6.37 percent to end at $73.21 apiece after the company posted an impressive earnings performance during the first three months of the year. In its earnings release, Verona Pharma plc (NASDAQ:VRNA) said that it narrowed its net loss by 36.8 percent to $16.3 million from $25.79 million in the same period a year earlier. Net revenues stood at $76.3 million, primarily driven by $71.3 million in net sales from Ohtuvayre, the company's maintenance treatment of COPD. In February this year, Verona Pharma plc (NASDAQ:VRNA), through its partner Nuance Pharma, secured the green light of the Macau government to sell Ohtuvayre in the special administrative region. Commenting on its strong performance, VRNA President and CEO David Zaccardelli said: 'We are extremely pleased to report that for the first time, Verona's quarterly revenue exceeded our operating expenses, excluding non-cash charges. We believe we are in a robust financial position to continue commercializing Ohtuvayre, advance our clinical pipeline, and implement our global strategy.' Overall VRNA ranks 6th on our list of the stocks that soared on Tuesday. While we acknowledge the potential of VRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than VRNA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
